{"title":"Immobilization of Bgps-Expressing Escherichia coli cells coated with ZIF-67 for the production of rare ginsenoside F1","authors":"","doi":"10.1016/j.bej.2024.109432","DOIUrl":null,"url":null,"abstract":"<div><p>Rare ginsenoside F1 is a potent medicinal component with low natural content. Currently, ginsenoside F1 is primarily produced through enzyme or microbial deglycosylation. Despite its high catalytic efficiency, biocatalyst reuse presents problems. Previously, we obtained ginsenoside hydrolase Bgps using gene mining and expressed it heterologously in <em>E. coli</em>. In this experiment, we immobilized Bgps-containing cells with ZIF-67 and used them for the synthesis of rare ginsenoside F1, thus solving the problem of poor reusability of free cells. Immobilized cells retained more than 80 % of the yield after five batches at 40 °C and pH 9.0 as compared to free cells, and their operational stability was significantly better. After 15 days at 4 °C, the immobilized cells preserved more than 70 % of their initial activity, remained stable, and showed good pH adaptation. This provides a green and sustainable method for the catalytic production of the rare ginsenoside F1 by immobilized cells.</p></div>","PeriodicalId":8766,"journal":{"name":"Biochemical Engineering Journal","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Engineering Journal","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1369703X24002195","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rare ginsenoside F1 is a potent medicinal component with low natural content. Currently, ginsenoside F1 is primarily produced through enzyme or microbial deglycosylation. Despite its high catalytic efficiency, biocatalyst reuse presents problems. Previously, we obtained ginsenoside hydrolase Bgps using gene mining and expressed it heterologously in E. coli. In this experiment, we immobilized Bgps-containing cells with ZIF-67 and used them for the synthesis of rare ginsenoside F1, thus solving the problem of poor reusability of free cells. Immobilized cells retained more than 80 % of the yield after five batches at 40 °C and pH 9.0 as compared to free cells, and their operational stability was significantly better. After 15 days at 4 °C, the immobilized cells preserved more than 70 % of their initial activity, remained stable, and showed good pH adaptation. This provides a green and sustainable method for the catalytic production of the rare ginsenoside F1 by immobilized cells.
期刊介绍:
The Biochemical Engineering Journal aims to promote progress in the crucial chemical engineering aspects of the development of biological processes associated with everything from raw materials preparation to product recovery relevant to industries as diverse as medical/healthcare, industrial biotechnology, and environmental biotechnology.
The Journal welcomes full length original research papers, short communications, and review papers* in the following research fields:
Biocatalysis (enzyme or microbial) and biotransformations, including immobilized biocatalyst preparation and kinetics
Biosensors and Biodevices including biofabrication and novel fuel cell development
Bioseparations including scale-up and protein refolding/renaturation
Environmental Bioengineering including bioconversion, bioremediation, and microbial fuel cells
Bioreactor Systems including characterization, optimization and scale-up
Bioresources and Biorefinery Engineering including biomass conversion, biofuels, bioenergy, and optimization
Industrial Biotechnology including specialty chemicals, platform chemicals and neutraceuticals
Biomaterials and Tissue Engineering including bioartificial organs, cell encapsulation, and controlled release
Cell Culture Engineering (plant, animal or insect cells) including viral vectors, monoclonal antibodies, recombinant proteins, vaccines, and secondary metabolites
Cell Therapies and Stem Cells including pluripotent, mesenchymal and hematopoietic stem cells; immunotherapies; tissue-specific differentiation; and cryopreservation
Metabolic Engineering, Systems and Synthetic Biology including OMICS, bioinformatics, in silico biology, and metabolic flux analysis
Protein Engineering including enzyme engineering and directed evolution.